UBS Group Lowers Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $24.00
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price target dropped by research analysts at UBS Group from $30.00 to $24.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 214.96% from the company’s previous close. Other […]
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price target dropped by research analysts at UBS Group from $30.00 to $24.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 214.96% from the company’s previous close. Other […]
